F-18 labelled “Pittsburgh compound B” or F18-PIB is a new, promising proprietary PET scanning agent for early imaging / detection of Alzheimers disease. The compound is owned by GE-Health Care, but we have been invited to assist in the early clinical trials as GMP compliant manufacturer of this new experimental drug.
Over a period of 3 years, we have set-up and validated the production and are now supplying clinical trials at Rigshospitalet in Copenhagen and elsewhere.